Tag: IXC

Invex Therapeutics ASX IXC Presendin Exenatide contract manufacturing organisation CMO

Invex Therapeutics narrows its search for preferred CMO to manufacture commercial quantities of Presendin

Biopharmaceutical company Invex Therapeutics (ASX: IXC) has identified several preferred formulation candidates and narrowed its search for a contract manufacturing organisation (CMO) that will manufa...
Invex Therapeutics ASX IXC FDA meeting advance Phase III trial Presendin treatment idiopathic intracranial hypertension

Invex Therapeutics granted FDA meeting to advance Presendin phase III trial for treating idiopathic intracranial hypertension

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has been granted a meeting with the US Food and Drug Administration to discuss the planned development pathway for its lead drug ...
Invex Therapeutics ASX IXC pre-IND meeting US FDA Presendin trial IIH sufferers

Invex Therapeutics files for pre-IND meeting with US FDA regarding Presendin™ trial in IIH sufferers

Invex Therapeutics’ (ASX: IXC) has filed a pre-investigational new drug application with the United States Food and Drug Administration for the proposed phase III trial evaluating its drug Presendin i...
Invex Therapeutics ASX IXC biotech Dr Megan Baldwin

Invex Therapeutics appoints biotech expert Dr Megan Baldwin to its board

Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has welcomed seasoned drug development expert Dr Megan Baldwin to the board as an independent non-executive director, effective t...
Invex Therapeutics ASX IXC idiopathic intracranial hypertension IIH phase 3 drug

Invex Therapeutics pushes on with phase three trial design to repurpose drug for brain disorder

Invex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use a diabetic drug for a neurological condition in desperate need for treatment. The biopharmaceuti...
Invex Therapeutics ASX IXC Idiopathic Intracranial Hypertension headache

Invex Therapeutics raises $26 million as it plans for Phase 3 clinical trial

Two days since publishing its Phase 2 clinical trial results and announcing “clear evidence” that its Exeatide drug is effective at reducing intracranial pressure in Idiopathic Intracranial Hypertensi...
Invex Therapeutics ASX IXC repurpose diabetic drug brain disorders Exenatide IPO

Invex Therapeutics aims to repurpose a diabetic drug for brain disorders

Biopharmaceutical company Invex Therapeutics is planning to make its ASX debut this week under the ticker code “IXC” with ambitions to repurpose an approved diabetes drug for some neurological conditi...